• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项范围综述,旨在了解卡麦角林在泌乳素瘤放射学和生化缓解方面的适应证、有效性及局限性。

A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

作者信息

Mishra Rakesh, Konar Subhas K, Shrivastava Adesh, Chouksey Pradeep, Raj Sumit, Agrawal Amit

机构信息

Department of Neurosurgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.

Department of Neurosurgery, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India.

出版信息

Indian J Endocrinol Metab. 2021 Nov-Dec;25(6):493-506. doi: 10.4103/ijem.ijem_338_21. Epub 2022 Feb 17.

DOI:10.4103/ijem.ijem_338_21
PMID:35355923
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8959198/
Abstract

Cabergoline has long been used in the medical management of prolactin-secreting pituitary adenomas. However, there is contradicting and inadequate evidence on the efficacy of cabergoline in achieving radiological and biochemical remission in prolactinoma. This article presents scoping review of evidence in cabergoline achieving radiological and biochemical remission in cases of prolactinoma. We have used a recommended scoping review methodology to map and summarize existing research evidence and identify knowledge gaps. The review process was conducted according to the PRISMA-ScR guidelines (Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews). The selection of studies was based on the criteria defined. Essential information such as reference details, study characteristics, topics of interest, main findings, and the study author's conclusion are presented in text and tables. With the study selection process, eight publications were finally included-one systematic review and meta-analysis, one RCT, and six primary studies. Cabergoline is effective in achieving biochemical and radiological remission in cases of prolactinoma. We identified several knowledge gaps with the scoping review and directions for future studies. Future studies, including randomized studies, will help address challenging questions associated with the management of prolactinoma.

摘要

卡麦角林长期以来一直用于分泌催乳素的垂体腺瘤的医学治疗。然而,关于卡麦角林在催乳素瘤中实现影像学和生化缓解的疗效,存在相互矛盾且不充分的证据。本文对卡麦角林在催乳素瘤病例中实现影像学和生化缓解的证据进行了范围综述。我们采用了推荐的范围综述方法来梳理和总结现有研究证据,并识别知识空白。综述过程按照PRISMA-ScR指南(系统评价和Meta分析扩展的范围综述的首选报告项目)进行。研究的选择基于所定义的标准。参考文献细节、研究特征、感兴趣的主题、主要发现以及研究作者的结论等基本信息在正文和表格中呈现。通过研究选择过程,最终纳入了八篇出版物——一篇系统评价和Meta分析、一篇随机对照试验和六篇原发性研究。卡麦角林在催乳素瘤病例中实现生化和影像学缓解方面是有效的。我们通过范围综述确定了几个知识空白以及未来研究的方向。未来的研究,包括随机研究,将有助于解决与催乳素瘤管理相关的具有挑战性的问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8a3/8959198/98ea0e0f0080/IJEM-25-493-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8a3/8959198/3532739e1188/IJEM-25-493-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8a3/8959198/98ea0e0f0080/IJEM-25-493-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8a3/8959198/3532739e1188/IJEM-25-493-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8a3/8959198/98ea0e0f0080/IJEM-25-493-g002.jpg

相似文献

1
A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.一项范围综述,旨在了解卡麦角林在泌乳素瘤放射学和生化缓解方面的适应证、有效性及局限性。
Indian J Endocrinol Metab. 2021 Nov-Dec;25(6):493-506. doi: 10.4103/ijem.ijem_338_21. Epub 2022 Feb 17.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis.药物治疗失败的泌乳素瘤的手术治疗结局:系统评价和荟萃分析。
Pituitary. 2021 Dec;24(6):978-988. doi: 10.1007/s11102-021-01188-7. Epub 2021 Sep 27.
4
Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.卡麦角林抵抗性泌乳素瘤中泌乳素对二甲双胍的反应:一项初步研究。
Neuroendocrinology. 2022;112(1):68-73. doi: 10.1159/000514591. Epub 2021 Jan 21.
5
Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.分泌催乳素和临床无功能垂体腺瘤患者中激素水平及肿瘤大小对喹高利特和卡麦角林的反应:123I-甲氧基苄胺垂体闪烁显像的预测价值
Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45. doi: 10.1046/j.1365-2265.2000.00951.x.
6
Hyperprolactinemia: pathophysiology and management.高催乳素血症:病理生理学与管理
Treat Endocrinol. 2003;2(1):23-32. doi: 10.2165/00024677-200302010-00003.
7
Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.卡麦角林治疗的泌乳素瘤患者当前的药物撤药策略:一项系统评价和荟萃分析。
Pituitary. 2015 Oct;18(5):745-51. doi: 10.1007/s11102-014-0617-2.
8
Hyperprolactinemia and prolactinoma.高催乳素血症与催乳素瘤。
Handb Clin Neurol. 2014;124:185-95. doi: 10.1016/B978-0-444-59602-4.00013-7.
9
PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.PRL-R 变异不仅与泌乳素瘤有关,而且与多巴胺激动剂抵抗有关。
J Clin Endocrinol Metab. 2023 Jun 16;108(7):e450-e457. doi: 10.1210/clinem/dgad020.
10
Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.儿童和青少年高泌乳素血症与泌乳素瘤病例的长期随访结果:单中心经验。
Turk J Pediatr. 2022;64(5):892-899. doi: 10.24953/turkjped.2021.4639.

本文引用的文献

1
Adult Langerhans Cell Histiocytosis Diagnosed by Biopsy of the Skull Tumor Generated after Craniotomy.通过开颅术后颅骨肿瘤活检诊断的成人朗格汉斯细胞组织细胞增多症
NMC Case Rep J. 2021 Apr 2;8(1):101-105. doi: 10.2176/nmccrj.cr.2020-0094. eCollection 2021 Apr.
2
Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis.儿童和青少年催乳素瘤-发病时的肿瘤大小预测治疗策略:单中心系列及系统评价和荟萃分析。
Clin Endocrinol (Oxf). 2021 Mar;94(3):413-423. doi: 10.1111/cen.14394. Epub 2020 Dec 26.
3
Predictors of the Response to Dopaminergic Therapy in Patients With Prolactinoma.
泌乳素瘤患者对多巴胺能治疗反应的预测因素。
J Clin Endocrinol Metab. 2020 Dec 1;105(12). doi: 10.1210/clinem/dgaa652.
4
Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.单中心儿童和青少年泌乳素瘤的临床、激素和神经影像学特征及治疗结果。
Front Endocrinol (Lausanne). 2020 Aug 4;11:527. doi: 10.3389/fendo.2020.00527. eCollection 2020.
5
Sellar Cholesterol Granuloma Mimicking Cystic Sellar Lesions: A Report of Three Cases and Literature Review.鞍内胆固醇肉芽肿酷似囊性鞍内病变:三例报告及文献复习。
World Neurosurg. 2020 Dec;144:250-255. doi: 10.1016/j.wneu.2020.07.234. Epub 2020 Aug 8.
6
Decrease of Proliferative Potential and Vascular Density of Giant Prolactinoma in Patients Treated with Cabergoline.卡麦角林治疗的巨大泌乳素瘤患者增殖潜能和血管密度的降低
Asian J Neurosurg. 2020 May 29;15(2):385-390. doi: 10.4103/ajns.AJNS_16_20. eCollection 2020 Apr-Jun.
7
Clinical Features, Therapeutic Trends, and Outcome of Giant Prolactinomas: A Single-Center Experience Over a 12-Year Period.巨大泌乳素瘤的临床特征、治疗趋势及预后:一项单中心12年经验研究
Clin Med Insights Endocrinol Diabetes. 2020 Jun 4;13:1179551420926181. doi: 10.1177/1179551420926181. eCollection 2020.
8
Predictors of dopamine agonist resistance in prolactinoma patients.泌乳素瘤患者中多巴胺激动剂抵抗的预测因素。
BMC Endocr Disord. 2020 May 19;20(1):68. doi: 10.1186/s12902-020-0543-4.
9
Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis.手术作为催乳素瘤患者一线治疗的可行选择:系统评价和荟萃分析。
J Clin Endocrinol Metab. 2020 Mar 1;105(3):e32-41. doi: 10.1210/clinem/dgz144.
10
Dopamine agonist resistant prolactinomas: any alternative medical treatment?多巴胺激动剂抵抗型催乳素瘤:有其他替代的医学治疗方法吗?
Pituitary. 2020 Feb;23(1):27-37. doi: 10.1007/s11102-019-00987-3.